Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway
Authors:
Open Access
- 17 September 2014
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 32 (6) , 2596-2604
Abstract
Nasopharyngeal carcinoma (NPC) is a leading cause of cancer-related mortality. Radiotherapy is one of the primary modalities for NPC treatment. However, in patients in the late stages of the disease, the local control rate and overall survival rate remain low. Therefore, it is urgent to identify new targets that can improve the outcome of radiotherapy in this neoplasm. In the present study, we investigated the effects of metformin on the radiosensitivity of NPC cells and explored the potential mechanisms. The radiosensitizing effects of metformin on NPC cells were measured by colony formation assay. Cell apoptosis was assessed by Hoechst 33342 staining analysis. DNA damage was detected by monitoring γ-H2AX foci with immunofluorescence. The changes in apotosis-related and DNA damage repair-related proteins were detected by western blotting. Our study demonstrated that metformin significantly reduced the cell viability, enhanced radiosensitivity and potentiated radiation-induced caspase-9/-3 cleavage in the NPC cells. In addition, metformin plus radiation significantly upregulated the expression of p-ATM, p-ATR, γ-H2AX and downregulated the expression of ATM, ATR, p95/NBS1, Rad50, DNA-PK, Ku70 and Ku80. Therefore, our results suggest that metformin possesses a strong radiosensitizing potential in NPC cells. This radiosensitizing effect was associated with inhibition of DNA double-strand break repair processes through HR repair and the NHEJ repair signaling pathway, thereby enhancing radiation-induced cell apoptosis. These findings imply that metformin is a potent radiation-sensitizing agent and may be a promising candidate for clinical evaluation as part of a combined regimen for the treatment of nasopharyngeal carcinoma.Keywords
This publication has 28 references indexed in Scilit:
- Metformin trims fats to restore insulin sensitivityNature Medicine, 2013
- Heavy LIFting: tumor promotion and radioresistance in NPCJournal of Clinical Investigation, 2013
- Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2013
- Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft modelsOncology Letters, 2012
- Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialThe Lancet Oncology, 2012
- Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?Molecular Cancer Therapeutics, 2010
- Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 2009
- Nasopharyngeal carcinomaThe Lancet, 2005
- Metformin and reduced risk of cancer in diabetic patientsBMJ, 2005
- Epidemiology of nasopharyngeal carcinomaSeminars in Cancer Biology, 2002